AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20814967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg
Number of subjects: 412
Study 20814967 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous teriparatide 20 µg
Number of subjects: 412
Study 20814967 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 5 mg
Number of subjects: 412
Study 20814967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 412
Study 18281442 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered before a high-fat or standard breakfast
Number of subjects: 0
Study 18281442 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered concurrently with a standard breakfast
Number of subjects: 0
Study 18281442 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox (20 mg/kg) administered under fasted conditions
Number of subjects: 0
Study 18281442 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered at least 30 minutes before a meal
Number of subjects: 0
Study 18281442 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered consistently at the same time before meals
Number of subjects: 0
Study 16476694 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 100 mg bid
Number of subjects: 200
Study 16476694 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 200 mg bid
Number of subjects: 200
Study 16476694 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 50 mg bid
Number of subjects: 200
Study 16476694 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg qd
Number of subjects: 200
Study 12965266 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFN-beta1a)
Number of subjects: 0
Study 12965266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14601905 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by surgery
Number of subjects: 55
Study 14601905 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 55
Study 9663832 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic data collection system
Number of subjects: 640
Study 8466418 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric (MYO) prosthetic hand
Number of subjects: 76
Study 8466418 — intervention group
Group type: COMPARATOR
Intervention: Body-powered (BP) prosthetic hand
Number of subjects: 76
Study 8466418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MYO and BP prosthetic hands
Number of subjects: 76
Study 30572339 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg Salvia officinalis capsules once a day for 2 consecutive months
Number of subjects: 90
Study 30572339 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day for 2 consecutive months
Number of subjects: 90
Study 29357859 — intervention group
Group type: EXPERIMENTAL
Intervention: IDN 5933 (Ginkgoselect®Plus) 120 mg twice daily for 6 months
Number of subjects: 47
Study 29357859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 27089068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential monotherapy (strategy 1)
Number of subjects: 508
Study 27089068 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up combination therapy (strategy 2)
Number of subjects: 508
Study 27089068 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with prednisone (strategy 3)
Number of subjects: 508
Study 27089068 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab (strategy 4)
Number of subjects: 508
Study 27089068 — intervention group
Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 508
Study 24891067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg per day for 6 days
Number of subjects: 21
Study 24891067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22340631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (250 mg/m2 I.V. on days 1, 8, and 15) + Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Number of subjects: 115
Study 22340631 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Number of subjects: 115
Study 22340631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (in CMP arm)
Number of subjects: 115
Study 21127358 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure device (Angio-Seal, St. Jude Medical, Inc.)
Number of subjects: 627
Study 21127358 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 627
Study 21127358 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure device (Angio-Seal, St. Jude Medical, Inc.) in patients with a history of hypertension
Number of subjects: 627
Study 21127358 — intervention group
Group type: COMPARATOR
Intervention: Manual compression in patients with a history of hypertension
Number of subjects: 627
Study 18822128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues intervention (teaches mothers to attend to their own physiological, cognitive, and emotional cues that signal anxiety and worry, and to use cognitive‐behavioural strategies to reduce distress; also teaches understanding and responding to infant cues)
Number of subjects: 0
Study 18822128 — intervention group
Group type: COMPARATOR
Intervention: Care group (receives general information about infant care)
Number of subjects: 0
Study 18822128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues intervention
Number of subjects: 0
Study 16026370 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion pump (CSII)
Number of subjects: 40
Study 16026370 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 40
Study 12447952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime or carbapenem monotherapy
Number of subjects: 165
Study 12447952 — intervention group
Group type: COMPARATOR
Intervention: Combination of cefepime and aminoglycoside
Number of subjects: 165
Study 10638409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg MDE
Number of subjects: 15
Study 10638409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8523940 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of inhaled terbutaline for two consecutive days
Number of subjects: 39
Study 8523940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8523940 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of inhaled terbutaline
Number of subjects: 39
Study 1936483 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + SU
Number of subjects: 50
Study 1936483 — intervention group
Group type: COMPARATOR
Intervention: Insulin + SU
Number of subjects: 50
Study 7013087 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline alone or in combination with fluphenazine hydrochloride
Number of subjects: 10
Study 31995132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Mood Balance (MMB) plus usual depression care (UDC)
Number of subjects: 460
Study 31995132 — intervention group
Group type: COMPARATOR
Intervention: Usual depression care (UDC)
Number of subjects: 460
Study 31544375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided acupoint electrical stimulation therapy (30 min, 3 times a day for 7 days)
Number of subjects: 52
Study 31544375 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 52
Study 28628560 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 2067
Study 28628560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067
Study 26402075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF: folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Number of subjects: 34
Study 26402075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24156189 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy with Emotional‐Approach Coping (MT/EAC)
Number of subjects: 37
Study 24156189 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk‐based Emotional‐Approach Coping (EAC)
Number of subjects: 37
Study 24156189 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 37
Study 24156189 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study 22368863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1 (10 mg x kg(‐1) administered intraperitoneally once a day)
Number of subjects: 96
Study 22368863 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Number of subjects: 96
Study 22368863 — intervention group
Group type: COMPARATOR
Intervention: Model group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Number of subjects: 96
Study 19702487 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH XR 10 mg o.d.
Number of subjects: 253
Study 19702487 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH XR 20 mg o.d.
Number of subjects: 253
Study 19702487 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH XR 30 mg o.d.
Number of subjects: 253
Study 19702487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 17494926 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine
Number of subjects: 5455
Study 17494926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5455
Study 15510233 — intervention group
Group type: EXPERIMENTAL
Intervention: Budenofalk 9 mg once daily (o.d.)
Number of subjects: 15
Study 15510233 — intervention group
Group type: EXPERIMENTAL
Intervention: Budenofalk 3 mg three times a day (t.i.d.)
Number of subjects: 15
Study 11562625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 0
Study 11562625 — intervention group
Group type: COMPARATOR
Intervention: Nebulized terbutaline
Number of subjects: 0
Study 9337466 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery tapes for three days before surgery, during anesthesia induction, intraoperatively, and for six days after surgery
Number of subjects: 130
Study 9337466 — intervention group
Group type: COMPARATOR
Intervention: Routine perioperative care
Number of subjects: 130
Study 7886398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 9
Study 7886398 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 9
Study 7886398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3126348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Number of subjects: 129
Study 3126348 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase 1,500,000 IU over 60 min
Number of subjects: 129
Study 3126348 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 129
Study 3126348 — intervention group
Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 129
Study 31680028 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider excision margins (2-3 cm)
Number of subjects: 1184
Study 31680028 — intervention group
Group type: COMPARATOR
Intervention: Narrower excision margins (1 cm)
Number of subjects: 1184
Study 29180023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (8.4 g/d or 16.8 g/d for 4 weeks)
Number of subjects: 100
Study 29180023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 100
Study 29180023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29178713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic-active toothbrush (SA)
Number of subjects: 72
Study 29178713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating toothbrush (OR)
Number of subjects: 72
Study 29178713 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 72
Study 29178713 — intervention group
Group type: EXPERIMENTAL
Intervention: All toothbrush systems
Number of subjects: 72
Study 29178713 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological analysis
Number of subjects: 72
Study 26651464 — intervention group
Group type: EXPERIMENTAL
Intervention: AVG group with SDT-based features turned on
Number of subjects: 0
Study 26651464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23822942 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) with concurrent phlebectomies
Number of subjects: 100
Study 23822942 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 100
Study 23822942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EVLA and UGFS
Number of subjects: 100
Study 23822942 — intervention group
Group type: COMPARATOR
Intervention: UGFS
Number of subjects: 100
Study 23822942 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant foam sclerotherapy
Number of subjects: 100
Study 21982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations with 1.0% and 5.0% panthenol
Number of subjects: 0
Study 21982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations with panthenol after skin washing with sodium laureth sulphate (SLES)
Number of subjects: 0
Study 21982351 — intervention group
Group type: COMPARATOR
Intervention: Control and vehicle (not specified)
Number of subjects: 0
Study 19393139 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 19393139 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 0
Study 17050890 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 527
Study 17050890 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 527
Study 12873431 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[1-13C] phenylalanine breath test (PBT)
Number of subjects: 25
Study 10539230 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 334
Study 10539230 — intervention group
Group type: COMPARATOR
Intervention: Family-based group intervention
Number of subjects: 334
Study 8909625 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based and school-based violence-prevention leadership program for peer leaders and their parents.
Number of subjects: 0
Study 1855327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with combined staphylococcus toxoid and whole killed staphylococci (SB)
Number of subjects: 124
Study 1855327 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (SS)
Number of subjects: 124
Study 6681030 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-monthly assessments
Number of subjects: 116
Study 6681030 — intervention group
Group type: COMPARATOR
Intervention: Yearly assessments
Number of subjects: 116
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing violence in Italy
Number of subjects: 503
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological violence
Number of subjects: 503
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical violence
Number of subjects: 503
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic violence
Number of subjects: 503
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence
Number of subjects: 503
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for violence
Number of subjects: 503
Study 30345306 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of episodes of violence
Number of subjects: 503
Study 27917802 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 400
Study 27917802 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 400
Study 27917802 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine
Number of subjects: 400
Study 27917802 — intervention group
Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 400
Study 24571702 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilised stannous (Sn)-containing NaF dentifrice (Oral B/blend-a-Med Pro-Expert)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Clinically proven, stabilised SnF2 positive control (Crest Pro-Health, 1,100 ppm F as SnF2)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Meridol (1,400 ppm F as AmF + SnF2)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Colgate Cavity Protection (1,450 ppm F as SMFP + NaF)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Odol med 3 (1,400 ppm F as NaF)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Elmex (1,400 ppm F as AmF)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Colgate Enamel Protect (1,450 ppm F as NaF + KNO3)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Lacalut aktiv (1,400 ppm F as AlF3)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Sensodyne ProNamel (1,450 ppm F as NaF + KNO3)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Crest Cavity Protection (1,100 ppm F as NaF, reference control)
Number of subjects: 4
Study 24571702 — intervention group
Group type: COMPARATOR
Intervention: Mentadent (1,450 ppm F as NaF + Zn citrate)
Number of subjects: 4
Study 22101220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood obesity intervention (no specific dosage or duration mentioned)
Number of subjects: 667
Study 22101220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention mentioned)
Number of subjects: 667
Study 20331333 — intervention group
Group type: EXPERIMENTAL
Intervention: INJEX needleless device
Number of subjects: 87
Study 20331333 — intervention group
Group type: COMPARATOR
Intervention: Classical infiltration anesthesia
Number of subjects: 87
Study 18246446 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (physicians received instant online graphical output of HRQoL data)
Number of subjects: 162
Study 18246446 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians conducted consultations as usual)
Number of subjects: 162
Study 16192762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with epinephrine (5 mug/ml)
Number of subjects: 20
Study 16192762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine without epinephrine
Number of subjects: 20
Study 14515631 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-submerged loaded (NSL) implants
Number of subjects: 14
Study 14515631 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-submerged non-loaded (NSNL) implants
Number of subjects: 14
Study 14515631 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged (S) implants
Number of subjects: 14
Study 10715512 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based tobacco use prevention intervention
Number of subjects: 8388
Study 8691863 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 units of fresh frozen plasma after operation
Number of subjects: 50
Study 8691863 — intervention group
Group type: COMPARATOR
Intervention: Gelofusine plasma substitute
Number of subjects: 50
Study 1549826 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting training
Number of subjects: 34
Study 1549826 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 3890461 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.0% indomethacin (5-drop loading dose, applied pre-operatively and post-operatively every 3 hours)
Number of subjects: 24
Study 3890461 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 phakic eyes with capsular glaucoma, lasered without indomethacin drops)
Number of subjects: 24
Study 31162654 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 0
Study 31162654 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 0
Study 29931588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) combined with functional exercise program (n=11)
Number of subjects: 22
Study 29931588 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (functional exercise program with placebo phototherapy) (n=11)
Number of subjects: 22
Study 27302432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% + epinephrine
Number of subjects: 60
Study 27302432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 3% + felypressin 0.03 units
Number of subjects: 60
Study 27302432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 3%
Number of subjects: 60
Study 23338616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention only
Number of subjects: 141
Study 23338616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus follow-up support
Number of subjects: 141
Study 23338616 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 141
Study 23279452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar injections containing a local anesthetic (lidocaine 0.5%, 6 mL)
Number of subjects: 120
Study 23279452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections of 0.5% lidocaine, 5 mL, mixed with 1 mL of non‐particulate betamethasone
Number of subjects: 120
Study 23279452 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 120
Study 20167441 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antiviral HCV therapy with pegylated interferon and ribavirin
Number of subjects: 26
Study 18322903 — intervention group
Group type: EXPERIMENTAL
Intervention: Beauty treatments during hospitalization
Number of subjects: 100
Study 18322903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beauty treatments)
Number of subjects: 100
Study 16002160 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 47